Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E2F transcription factor 3 pseudogene 2 (E2F3P2) is a pseudogene in the human genome[3][1][5]. Pseudogenes are genomic DNA sequences similar to normal genes but are non-functional; they typically do not encode a functional protein product and generally lack biological activity. E2F3P2 shares sequence similarity with E2F transcription factor 3 (E2F3), a true transcription factor involved in cell cycle regulation, but E2F3P2 itself does not function as a receptor, enzyme, or direct therapeutic target[3][1][5]. There is no evidence in the literature or gene databases of E2F3P2 serving as a target for drugs, being implicated in clear biological functions, or acting as a biomarker or mediator in disease. Some sources list a disease association with atrial fibrillation, but this appears to be an annotation error or only a bioinformatics association, with no validated mechanistic link[3]. Therefore, E2F3P2 is not a functional molecule in pharmacology or cellular signaling, and inclusion of this entry as a drug target would be considered incorrect[3][1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E2F transcription factor 3 pseudogene 2 (E2F3P2).